1090TiP A phase II, open label, multicenter study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with treatment-naïve metastatic Merkel cell carcinoma: The MERKLIN 1 study
Year: 2021
Type: article
Source: Annals of Oncology
Authors: P.A. Ascierto, A.C.J. van Akkooi, P. Nghiem, F. Hermann, J-P. Henneberg, J.C. Becker
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Gilead Sciences, Array BioPharma, Regeneron Pharmaceuticals, Exelixis, Les Laboratories Pierre Fabre, Astex Pharmaceuticals, Incyte, Syndax Pharmaceuticals, Moderna, Seagen, Eisai, Sun Pharma, Italfarmaco, NeraCare, Genentech, Daiichi Sankyo Europe
OpenAlex ID: W3204130070